Related Experiment Video
Updated: Feb 20, 2026
Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line
Published on: February 17, 2016
Surface marker profiling of SH-SY5Y cells enables small molecule screens identifying BMP4 as a modulator of
Fraua Christina Ferlemann1,2, Vishal Menon1,3, Alexandra Larisa Condurat1,3
1Emmy-Noether-Group for Stem Cell Biology, Department of Molecular Embryology, Institute of Anatomy and Cell Biology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Abstract:
Neuroblastoma is the most common extra-cranial solid tumor in children. Its broad spectrum of clinical outcomes reflects the underlying inherent cellular heterogeneity. As current treatments often do not lead to tumor eradication, there is a need to better define therapy-resistant neuroblastoma and to identify new modulatory molecules. To this end, we performed the first comprehensive flow cytometric characterization of surface molecule expression in neuroblastoma cell lines. Exploiting an established clustering algorithm (SPADE) for unbiased visualization of cellular subsets, we conducted a multiwell screen for small molecule modulators of neuroblastoma phenotype. In addition to SH-SY5Y cells, the SH-EP, BE(2)-M17 and Kelly lines were included in follow-up analysis as in vitro models of neuroblastoma. A combinatorial detection of glycoprotein epitopes (CD15, CD24, CD44, CD57, TrkA) and the chemokine receptor CXCR4 (CD184) enabled the quantitative identification of SPADE-defined clusters differentially responding to small molecules. Exposure to bone morphogenetic protein (BMP)-4 was found to enhance a TrkAhigh/CD15-/CD184- neuroblastoma cellular subset, accompanied by a reduction in doublecortin-positive neuroblasts and of NMYC protein expression in SH-SY5Y cells. Beyond yielding novel marker candidates for studying neuroblastoma pathology, our approach may provide tools for improved pharmacological screens towards developing novel avenues of neuroblastoma diagnosis and treatment.
Insights
This study characterizes neuroblastoma cell surface molecules using flow cytometry and SPADE clustering. Bone morphogenetic protein-4 treatment enhanced a specific neuroblastoma subset, offering new diagnostic and therapeutic targets.
Area of Science:
- Pediatric Oncology
- Cellular Heterogeneity
- Cancer Biology
Background:
- Neuroblastoma, a common childhood cancer, exhibits diverse clinical outcomes due to cellular heterogeneity.
- Current treatments struggle with tumor eradication, necessitating research into therapy-resistant neuroblastoma and new therapeutic targets.
Purpose of the Study:
- To comprehensively characterize surface molecule expression in neuroblastoma cell lines using flow cytometry.
- To identify small molecule modulators of neuroblastoma phenotype and cellular subsets.
- To discover novel diagnostic markers and therapeutic strategies for neuroblastoma.
Main Methods:
- Comprehensive flow cytometric characterization of neuroblastoma cell lines (SH-SY5Y, SH-EP, BE(2)-M17, Kelly).
- Application of SPADE clustering for unbiased visualization and identification of cellular subsets.
- Multiwell screening of small molecules to identify modulators of neuroblastoma phenotype and surface marker expression (CD15, CD24, CD44, CD57, TrkA, CXCR4/CD184).
Main Results:
- Identification of distinct neuroblastoma cellular subsets based on surface molecule expression.
- Bone morphogenetic protein (BMP)-4 exposure enhanced a TrkAhigh/CD15-/CD184- subset.
- BMP-4 treatment led to reduced doublecortin-positive neuroblasts and NMYC protein expression in SH-SY5Y cells.
Conclusions:
- The study provides novel surface marker candidates for neuroblastoma pathology research.
- The developed approach offers tools for improved pharmacological screening.
- This research may lead to new avenues for neuroblastoma diagnosis and treatment.
More Related Videos
13:47TIRFM and pH-sensitive GFP-probes to Evaluate Neurotransmitter Vesicle Dynamics in SH-SY5Y Neuroblastoma Cells: Cell Imaging and Data Analysis
Published on: January 29, 2015
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023